α -Ketoglutarate (α KG) is a key node in many important metabolic pathways. The α KG analog N-oxalylglycine (NOG) and its cell-permeable prodrug dimethyloxalylglycine (DMOG) are extensively used to inhibit α KG-dependent dioxygenases. However, whether NOG interference with other α KG-dependent processes contributes to its mode of action remains poorly understood. Here we show that, in aqueous solutions, DMOG is rapidly hydrolyzed, yielding methyloxalylglycine (MOG). MOG elicits cytotoxicity in a manner that depends on its transport by monocarboxylate transporter 2 (MCT2) and is associated with decreased glutamine-derived tricarboxylic acid-cycle flux, suppressed mitochondrial respiration and decreased ATP production. MCT2facilitated entry of MOG into cells leads to sufficiently high concentrations of NOG to inhibit multiple enzymes in glutamine metabolism, including glutamate dehydrogenase. These findings reveal that MCT2 dictates the mode of action of NOG by determining its intracellular concentration and have important implications for the use of (D)MOG in studying α KG-dependent signaling and metabolism.
M any tumors have increased reliance on glutamine utilization, a process known as glutaminolysis 1 , which is promoted by major oncogenic pathways 2, 3 . Glutamine can contribute to biosynthetic processes directly or after conversion to glutamate by glutaminases 1 . Glutamate can then be deaminated to α KG (1 ) , which has pleiotropic roles in cell physiology 4 from tricarboxylic acid (TCA)-cycle metabolism to epigenetic regulation. Glutamate deamination is catalyzed either by glutamate dehydrogenase (GDH), thus producing α KG and ammonia, or by transaminases (TAs) that transfer the amino group of glutamate onto a recipient α -ketoacid, thereby generating a nonessential amino acid. In addition to glutaminases, both GDH and TAs have been implicated in cancer 3 . α KG can also be metabolized via isocitrate dehydrogenase (IDH) in a process known as reductive carboxylation (RC). RC mediates synthesis of fatty acids from glutamine 5 and is important for cancer cell survival after matrix detachment by supporting the detoxification of reactive oxygen species 6 .
α KG is also a cosubstrate, together with oxygen and the cofactor iron, for α KG-dependent dioxygenases (α KGDDs), a family of approximately 60 enzymes with broad-ranging substrates and functions 7 . Prolyl hydroxylases (PHDs) are among the most studied dioxygenases, particularly because of their role in regulating hypoxia signaling. PHD-catalyzed hydroxylation of hypoxia-inducible transcription factors (HIFs) tags these proteins for proteasome-mediated degradation 8 . Because PHD activity is oxygen dependent, hypoxia inhibits the hydroxylation of HIF and leads to its stabilization.
In support of the functional importance of α KG, oncogenic mutations in various TCA-cycle enzymes generate oncometabolites that inhibit α KGDD activity by competing with α KG for binding to the catalytic pocket 8, 9 . Similarly, exogenous α KG alone, or in combination with other metabolites, can complement inhibition of glutaminolysis [10] [11] [12] , thus suggesting that, although glutamine may have diverse roles in cells, α KG is a major mediator of glutaminesupported cancer metabolism.
Genetic-ablation studies in mice have suggested that inhibition of PHD function can be beneficial in various pathological settings [13] [14] [15] ; these findings have prompted the development of small-molecule inhibitors of PHD activity 9, 16 , which commonly function by competing with α KG for the PHD catalytic pocket 17 . NOG (2 ; Fig. 1a ) is an α KG analog in which the central methylene group of α KG is replaced with an NH moiety. NOG inhibits collagen prolyl hydroxylases 18 as well as several α KGDDs [19] [20] [21] but displays minimal plasma membrane permeability; therefore, in cellular and animal studies, it is administered as the prodrug DMOG (3 ; Fig. 1a ), which is deesterified within cells, thus forming NOG 22 . Importantly, DMOG administration to mice mimics the effects of genetic PHD inactivation 23, 24 , a finding that instigated the development of α KGDD inhibitors for various disease conditions 9 .
Beyond interfering with dioxygenase function, α KG analogs such as NOG are likely to affect other α KG-dependent metabolic and signaling processes. Some of the inferred roles of PHDs, primarily through stabilization of HIF1α , have been linked to metabolism, and, in some cases, DMOG has been used as a means to study these processes 14, [25] [26] [27] . However, little is known about the direct effects of NOG on α KG metabolism. Therefore, understanding its mode of action is important for interpreting its functional effects.
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG
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Here we show that DMOG is selectively toxic to cells that express monocarboxylate transporter 2, which we identify as a transporter of MOG (4 ; Fig. 1a ), a previously undescribed product of DMOG hydrolysis. MCT2 facilitates MOG entry into cells, thus leading to concentrations of NOG that are sufficiently high to inhibit multiple metabolic pathways, as exemplified by GDH, which binds NOG with low affinity, thereby attenuating glutamine metabolism through the TCA cycle.
Results
Selective DMOG toxicity is independent of αKGDD inhibition. DMOG is widely used to study hypoxia signaling in cells, because its hydrolysis product NOG inhibits PHDs, thereby leading to stabilization of HIF1α (refs. 19, 20 ) . We observed that treatment of different human breast cancer (BrCa) cell lines with DMOG inhibited cell-mass accumulation to varying degrees (Fig. 1b) , and, in sensitive cells, the morphological changes were consistent with cell death ( Supplementary Fig. 1a ). Using MCF7 and HCC1569 cells as model 'sensitive' and 'resistant' lines, respectively, we observed increased propidium iodide (PI) staining only in MCF7 cells ( Fig. 1c and Supplementary Fig. 1b ), thus suggesting that the DMOG-induced inhibition of cell-mass accumulation was due to cytotoxicity.
To test whether inhibition of dioxygenases accounted for differential sensitivity to DMOG, we cultured MCF7 and HCC1569 cells in 1% oxygen to inhibit dioxygenases 8 . We observed that, in agreement with dioxygenase inhibition, HIF1α protein levels increased in both MCF7 and HCC1569 cells ( Supplementary Fig. 1c ). Hypoxia, compared with normoxia, did not affect viability (Fig. 1c ) . Spearman's rank correlation coefficient is shown in the top right corner. Right, Spearman's rank correlation coefficient of SLC16A7 (black dashed line) with respect to those of all other transcripts. Gray shaded region on either side indicates ± 2-s.d. cutoff used to define sensitivity-associated genes. e, Western blot to assess MCT2 protein expression in lysates from BrCa cell lines used in b. The experiment was performed once. MW, molecular weight. Actin (β -actin), loading control. An uncropped blot is shown in Supplementary Fig. 13a .
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NATure CHeMiCAl BiOlOGy but decreased cell-mass accumulation similarly for both cell lines ( Supplementary Fig. 1d ). Nevertheless, MCF7 cells had identical half-maximal inhibitory concentrations for DMOG (IC 50 DMOG ) in both conditions ( Supplementary Fig. 1e ), and the kinetics of HIF1α stabilization by DMOG was similar between sensitive and resistant cells ( Supplementary Fig. 1c ). These data suggested that the selective cytotoxicity of DMOG cannot be explained by differential sensitivity to α KGDD inhibition.
DMOG toxicity correlates with MCT2 expression.
To identify factors that contribute to selective DMOG cytotoxicity, we probed data from the Genomics of Drug Sensitivity in Cancer project (http:// www.cancerrxgene.org/) 28 , in which the DMOG IC 50 (IC 50 DMOG ) was determined for 850 cell lines with available gene expression data. Similarly to the results in our BrCa cell lines, DMOG inhibited cell viability with a broad range of IC 50 values (0.010-58 mM) across all tested cancer types ( Supplementary Fig. 2a ). We defined (Methods) a set of 341 gene transcripts that negatively correlated (high expression and low IC 50 DMOG ) and 557 gene transcripts that positively correlated with IC 50 DMOG (Supplementary Dataset 1). SLC16A7, a transcript that encodes MCT2 (ref. 29 ), showed the highest correlation (ρ = -0.412) with sensitivity ( Fig. 1d ). MCT2 belongs to the solute carrier 16 (Slc16) family of transporters, which comprises 14 members, including MCT1 (encoded by SLC16A1) and MCT4 (encoded by SLC16A3), which are the best-studied MCTs and have both been implicated in cancer 30 . Neither SLC16A1 nor SLC16A3 was present in the list of IC 50 DMOG -correlating transcripts ( Supplementary Fig. 2b,c) , but, interestingly, EMB, which encodes Embigin, an accessory protein involved in trafficking of MCT2 to the plasma membrane 29 , was the fourth transcript most highly correlated with DMOG sensitivity ( Supplementary Fig. 2d and Supplementary Dataset 1).
In agreement with the IC 50 DMOG correlation at the transcript level, MCT2 protein expression was higher in DMOG-sensitive BrCa cell lines ( Fig. 1e ). We also investigated whether MCT2 expression correlated with DMOG sensitivity in cancer cell lines from other tissues of origin ( Supplementary Fig. 2e ). To that end, we selected high-sensitivity cell lines within different tissue-of-origin groups and confirmed that they had low IC 50 DMOG values (comparable to those for MCF7). Interestingly, MCT2 expression was variable, thus indicating that even low amounts of MCT2 are sufficient to confer sensitivity ( Supplementary Fig. 2e ,f). These data suggested that expression of MCT2 is linked to DMOG-induced cytotoxicity.
The methyl oxoacetate ester of DMOG is rapidly hydrolyzed. We hypothesized that, as a transporter, MCT2 might mediate DMOGinduced cytotoxicity by facilitating DMOG entry into cells. We developed a liquid chromatography-mass spectrometry (LC-MS) assay for the detection of DMOG ( Fig. 2a ) and its predicted end product, NOG (Fig. 2b) . In control experiments, we observed loss of DMOG signal from culture medium even in the absence of cells ( Supplementary Fig. 3a ). However, we did not detect NOG, thus suggesting that DMOG degraded to an unknown product. Inspection of the chromatograms of DMOG standard after a 20-h incubation in water revealed an unknown peak dominated by an ion with m/z 160.0252 ( Fig. 2c ). Because the mass difference to DMOG (m/z 174.0406) Δ m/z = 14, indicated loss of a single methyl group, we tentatively designated this ion species MOG.
We next used nuclear magnetic resonance (NMR) spectroscopy to determine which of the two methyl groups of DMOG was hydrolyzed. 1 H-NMR of DMOG incubated for 20 h in RPMI showed that the major DMOG peaks at 4.14, 3.77 and 3.92 p.p.m. were lost, whereas methanol and two low-abundance peaks (3.76 and 4.07 p.p.m.) increased (Fig. 2d ). These data indicated that the 3.76 and 4.07 peaks corresponded to products that arose from ester hydrolysis of DMOG, a process releasing methanol. Further analyses assigned m/z Fig. 2 | The methyl oxoacetate ester of DMOG is rapidly hydrolyzed to MOG in cell culture medium. a, LC-MS base-peak chromatogram and corresponding mass spectrum of 10 µ M DMOG in water, with peak and ion annotated. b, LC-MS base-peak chromatogram and corresponding mass spectrum of 10 µ M NOG in water, with peak and ion annotated. c, LC-MS base-peak chromatogram demonstrating the MOG peak formed after incubation in water for 20 h at room temperature. Right, mass spectrum of the MOG peak, with the ion corresponding to MOG annotated. d, 1D 1 H-NMR spectra of DMOG freshly resuspended in RPMI medium or after incubation in RPMI medium overnight, with or without the addition of a synthesized MOG standard. Signals are annotated according to the labeled structure of DMOG in e, with DMOG peaks with blue numbers and MOG peaks with red numbers. e, 2D 1 H, 13 C-HMBC-NMR spectrum of DMOG incubated in RPMI medium, with DMOG peaks with blue numbers and MOG peaks with red numbers, overlapping the cross-peak shown in purple. Right, DMOG structure annotated with the relevant 13 C signal shifts. Data are representative of more than three independent experiments yielding similar results.
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NATure CHeMiCAl BiOlOGy the 1 H-NMR resonances at 3.92 p.p.m. to the protons of the methyl oxoacetate moiety (Methods and Fig. 2e ). In line with this interpretation, the MOG authentic standard had an identical retention time and m/z ( Supplementary Fig. 3b ) to the ion that we observed by LC-MS in Fig. 2c , and an 1 H-NMR spectrum that precisely superimposed those signals corresponding to the DMOG degradation species (Fig. 2d ). These results conclusively showed that the methyl oxoacetate ester within DMOG is hydrolyzed, thereby forming the oxoacetic acid derivative MOG ( Fig. 1a ). DMOG conversion to MOG in RPMI medium was complete in < 1 h (half-life (t ½ ) = 7.5 min; Supplementary Fig. 3c ,d) and also occurred in water, albeit at a slower rate (t ½ = 6.5 h; Supplementary  Fig. 3e ). These results suggested that the selective hydrolysis of the methyl oxoacetate ester is nonenzymatic and is likely to be due to the α effect 31 . Additional analyses revealed that proton release during hydrolysis acidified the medium and attenuated further hydrolysis, whose rate is therefore influenced by the buffering capacity of the medium ( Supplementary Fig. 4 ). Collectively, these data showed that, in buffered aqueous solutions, DMOG is rapidly converted to MOG.
MCT2-mediated MOG transport correlates with cytotoxicity.
The rapid DMOG-to-MOG conversion raised the possibility that MOG is sufficient to elicit cytotoxicity. In agreement with this idea, DMOG and MOG inhibited cell-mass accumulation equally in MCF7 cells, whereas NOG had no effect ( Fig. 3a ). Furthermore, the intracellular NOG concentration ([NOG] ic ) was similarly high in MCF7 cells treated with either DMOG or MOG ( Fig. 3b ). Intracellular MOG was not detected, thus suggesting rapid hydrolysis of the methyl-glycinate moiety in cells. Under these experimental conditions, HCC1569 cells had more than tenfold-lower [NOG] ic when they were incubated with either DMOG or MOG (Fig. 3b ). Lower [NOG] ic correlated with lower cytotoxicity (Fig. 3a) . We observed minimal [NOG] ic when either cell line was treated with NOG itself, thus showing that NOG is not transported into these cells. These results suggested that MOG-induced toxicity is due to higher [NOG] ic in sensitive cells than resistant cells. Furthermore, because the conversion of DMOG to MOG in medium occurred in < 1 h, and both compounds induced comparable cytotoxicity, these data indicated that MOG is the active cytotoxic compound in medium. Hence, we used MOG to further explore the mechanism of cytotoxicity.
Because our gene expression correlation analysis implicated MCT2 in cell sensitivity to DMOG, we next tested whether exogenous MCT2 expression might sensitize the cells to MOG and whether this sensitization might be related to [NOG] ic . The IC 50 MOG of MOG-resistant HCC1569 cells (HCC1569-EV) was 2.26 ± 0.35 mM ( Fig. 3c and Supplementary Fig. 5a ). Stable expression of MCT2 in these cells (HCC1569-MCT2) decreased the IC 50 MOG to 0.31 ± 0.03 mM with a concomitant 12-fold increase in [NOG] ic after a 4-h incubation with MOG ( Fig. 3d ). Similarly to the results in Fig. 3b , minimal NOG was detected in cells incubated with NOG in the medium, in either HCC1569-EV or HCC1569-MCT2 cells ( Supplementary Fig. 5b ), thus confirming that NOG cannot enter cells via either the plasma membrane or MCT2. These results suggested that expression of MCT2 leads to increased [NOG] ic and therefore to increased sensitivity to MOG. To test whether MCT2 is necessary for MOG uptake, we stably knocked down MCT2 in MCF7 cells (MCF7-shMCT2 cells) ( Supplementary Fig. 5a ). The IC 50 MOG of MCF7-shMCT2 cells was 65% lower than that of control MCF7 cells (MCF7-pLKO cells) ( Fig. 3e ), and [NOG] ic decreased by 72% ( Fig. 3f ). Collectively, these data showed that MCT2 expression determines [NOG] ic and thereby modulates MOG-induced cytotoxicity.
Given the varying MCT2 levels among sensitive lines ( Supplementary Fig. 2e ,f), we measured [NOG] ic and toxicity in cells engineered to express doxycycline-inducible MCT2 ( Supplementary   Fig. 5c ). We found that 12% of maximal MCT2 expression was sufficient to attain half-maximal [NOG] ic ( Supplementary Fig. 5d ), whereas half-maximal toxicity occurred at just 3% of MCT2 maximal expression ( Supplementary Fig. 5e ) and correlated well with [NOG] ic ( Supplementary Fig. 5f ). These data indicated that even low levels of MCT2 can lead to sufficiently high [NOG] ic to elicit toxicity.
Because MOG is a monocarboxylate, we asked whether other MCTs might also mediate its transport into cells, focusing on MCT1 and MCT4, which share similar endogenous substrates with MCT2. We expressed MCT1, MCT2 or MCT4 in INS1 cells, a rat pancreatic beta-cell line with very low endogenous MCT activity 32 ( Supplementary Fig. 6a ). MCT2 expression led to the highest [NOG] ic after MOG treatment and was followed by MCT1 and MCT4 ( Supplementary Fig. 6b ), as reflected by the corresponding IC 50 MOG values ( Supplementary Fig. 6c ). These results indicated that MCT1 and MCT4 can transport MOG, albeit less efficiently than MCT2. MCT2 has the highest affinity (followed by MCT1 and MCT4) for all tested substrates, with a tenfold selectivity for pyruvate (5 ) over lactate (6 ) 33 . MOG treatment of MCF7 cells in the presence of superstoichiometric pyruvate levels, compared with MOG alone, resulted in an 83 ± 3.5% decrease in [NOG] ic ( Supplementary  Fig. 6d ), whereas superstoichiometric lactate only minimally decreased the [NOG] ic . Accordingly, pyruvate but not lactate, prevented MOG-induced toxicity ( Supplementary Fig. 6e ). Together, these data showed that although other members of the MCT family can transport MOG, MCT2 is the primary MOG transporter, a result reflecting its higher affinity for endogenous substrates.
High [NOG] ic inhibits glutamine catabolism and respiration.
MOG cytotoxicity is associated with increased [NOG] ic but not with differential engagement of its known substrates, dioxygenases, in sensitive cells ( Fig. 1 ). Because NOG is an α KG analog, high [NOG] ic might influence metabolism. To test this possibility, we treated MCF7 cells with MOG and analyzed metabolite concentrations over time. Within 1 h of treatment, several TCA intermediates (citrate, α KG, fumarate and malate) were depleted, and a subsequent increase in amino acid levels was observed at 2-4 h ( Fig. 4a and Supplementary Fig. 7a ). The increased amino acids were not due to attenuated translation ( Supplementary Fig. 7b ), as further supported by the observation that the nonproteinogenic amino acids ornithine and GABA also increased. We observed similar metabolic changes in HCC1569-MCT2 but not HCC1569-EV cells ( Supplementary Fig. 7c ). However, these metabolic effects were less pronounced in MCF7-shMCT2 cells ( Supplementary Fig. 7d ), thus indicating that they occur in an MCT2-dependent manner. MOG induced similar metabolic changes across other sensitive cell lines ( Supplementary Fig. 7e ). Importantly, the metabolic effects of MOG were not due to HIF1α stabilization, because they were preserved in MCF7 cells defective in HIF1α function ( Supplementary Fig. 8a,b) , which also retained sensitivity to MOG ( Supplementary Fig. 8c ).
To investigate the cause of TCA-cycle-intermediate depletion, we labeled MCF7 cells with [U-13 C]glucose or [U-13 C]glutamine in the presence or absence of MOG. MOG treatment decreased labeling from [U-13 C]glutamine, but not from [U-13 C]glucose, into TCA intermediates (Fig. 4b ). This finding was associated with a 56 ± 24% decrease in fully labeled (m + 5) α KG that was produced from [U-13 C]glutamine, although the proportion of fully labeled (m + 5) glutamate remained largely unchanged ( Fig. 4c ). Together, these data showed that treatment of cells with MOG inhibits entry of glutamine-derived carbons into the TCA cycle at the point of glutamate-to-α KG conversion.
A major function of glutamine-fueled TCA metabolism is ATP production through respiration 34 . MOG-treated MCF7 cells showed a 29 ± 5.7% decrease in oxygen consumption relative to basal respiration, a result similar to that found in H1299 cells expressing Articles NATure CHeMiCAl BiOlOGy inducible MCT2 ( Fig. 4d and Supplementary Fig. 9a ) and consistent with findings from a previous report 35 . Decreased respiration was associated with a significant decrease in ATP levels within 4 h in MOG-treated MCF7 cells ( Fig. 4e ) and in a number of cell lines ( Supplementary Fig. 9b ). Similarly, ATP levels decreased in MOGtreated HCC1569-MCT2 cells, but not in the control HCC1569-EV cells, whereas MOG did not decrease ATP levels in MCF7-shMCT2 cells ( Supplementary Fig. 9c ). These observations showed that decreased TCA-cycle flux in MOG-treated cells is accompanied by impaired respiration and decreased ATP levels.
αKG replenishes TCA and partly rescues MOG cytotoxicity. To explore whether MOG-induced inhibition of TCA metabolism is related to cytotoxicity, we treated MCF7 cells with MOG in the presence of dimethyl-glutamate (DM-Glu) or dimethyl-α KG (DM-α KG), cell-permeable analogs of glutamate and α KG, respectively. DM-Glu restored 50% of the decrease in glutamate levels but did not prevent MOG-induced cytotoxicity or the decrease in abundance of TCA intermediates ( Supplementary Fig. 10a-c) . DM-α KG increased α KG levels in a concentration-dependent manner and, although the magnitude of the MOG-induced decrease was preserved regardless of the total α KG pool size ( Supplementary  Fig. 10d ), DM-α KG restored the levels of most TCA intermediates and suppressed the MOG-induced increase in amino acid levels ( Supplementary Fig. 10e ). Furthermore, addition of α KG fully prevented the inhibition of glutamine-driven respiration by MOG 
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NATure CHeMiCAl BiOlOGy in MCF7 cells ( Supplementary Fig. 10f ). Supplementation of the medium with DM-α KG doubled the IC 50 MOG of MCF7 cells (Fig. 4f) , thus suggesting that replenishment of TCA intermediates with an exogenous source of α KG can alleviate MOG-induced toxicity. Together, these results showed that, in contrast to exogenous glutamate, exogenous α KG can restore TCA intermediates and respiration and partly rescue MOG-induced death.
NOG inhibits multiple targets in glutamine metabolism. To gain insight into the NOG targets that mediate the observed metabolic changes, we further examined the [U-13 C]glutamine labeling experiments. Glutamate can be converted to α KG by either TAs or GDH; to test for the involvement of the former, we compared the labeling pattern of metabolites from [U-13 C]glutamine in cells treated with MOG or aminooxyacetate (AOA), a pan-transaminase inhibitor. AOA caused an increase in the glutamate m + 5 isotopolog but, unlike MOG, did not change α KG m + 5 (Fig. 5a ) or labeling of TCA intermediates ( Supplementary Fig. 11a ). These results suggested that, similarly to other cell lines 11 , TAs do not significantly contribute substrates to the TCA cycle in MCF7 cells. Therefore, inhibition of TAs by MOG cannot account for the decreased labeling of TCA metabolites from [U-13 C]glutamine, thereby implicating GDH as the relevant NOG target.
Intriguingly, the finding that AOA also caused a decrease in glutamate m + 3 indicated that in MCF7 cells, transaminases use α KG m + 3 produced from the first turn of the TCA cycle as a nitrogen acceptor to degrade amino acids ( Fig. 5b ). MOG caused a decrease in glutamate m + 3, similarly to AOA, but also caused an increase in α KG m + 3, thus suggesting that in MOG-treated cells, TAs are inhibited in the glutamate-producing direction. This interpretation is supported by the observation that MOG-treated cells contained a lower α KG/glutamate ratio ( Supplementary Fig. 11b ), which would shift the equilibrium of TA reactions against glutamate production.
In agreement with this model, MOG treatment led to increased amino acid concentrations (Fig. 4a ). Together, these findings suggest that inhibition of GDH by NOG contributes to attenuation of the TCA cycle and a lower α KG/glutamate ratio that indirectly inhibits amino acid degradation by transaminases.
In MOG-treated MCF7 cells labeled with [U-13 C]glutamine, we also observed decreased labeling in citrate m + 5, fumarate m + 3 and aspartate m + 3 ( Fig. 5c and Supplementary Fig. 11c ), compounds produced via RC of α KG 6 . To assess whether the decreased reductive TCA flux was also due to GDH inhibition, we labeled cells with DM-[ 13 C 5 ]α KG (7 ) used at 0.1 mM, a concentration that minimally perturbs metabolism ( Supplementary Fig. 11d ). MOG inhibited labeling from DM-[ 13 C 5 ]α KG in citrate m + 5, but not citrate m + 4 ( Fig. 5d and Supplementary Fig. 11c ), whose levels actually increased, probably as a result of a decreased unlabeled carbon contribution from glutamine into this isotopolog during MOG treatment. These data indicated that inhibition of RC by MOG occurs downstream of α KG, in agreement with the target being IDH, which has been shown to be inhibited by NOG in vitro 36 . Importantly, the 13 C incorporation into RC-produced isotopologs of TCA intermediates decreased even when cells were labeled with 1 mM DM-[ 13 C 5 ]α KG, thus demonstrating that IDH inhibition is not fully rescued by DM-α KG ( Fig. 5e and to Supplementary Fig. 11c ) and possibly explaining why the rescue of toxicity by DM-α KG was only partial (Fig. 4f) .
In summary, these results provided evidence that MOG treatment independently inhibits both the oxidative and reductive TCA cycle, as well as amino acid degradation, thus indicating that NOG simultaneously engages multiple targets in glutamine metabolism.
NOG binds and inhibits GDH with low affinity. DM-α KG attenu-
ates MOG-induced toxicity associated with inhibition of oxidative TCA-cycle flux, which is mediated through GDH. We therefore focused on this enzyme to explore the basis of high [NOG] ic -dependent metabolic changes. WaterLOGSY NMR showed that NOG binds bovine GDH directly with K d NOG = 10 mM, a value comparable to that of α KG (4.6 mM) ( Fig. 6a and Supplementary  Fig. 12a ). Accordingly, we observed a dose-dependent decrease in GDH activity in MCF7 mitochondrial lysates ( Fig. 6b ) and purified GDH ( Supplementary Fig. 12b ), with IC 50 values of 3.05 ± 1.39 mM and 6.09 ± 2.20 mM, respectively, thus confirming that NOG inhibits GDH activity.
Considering the high K d NOG for GDH, we asked whether NOG accumulates at sufficient concentrations to inhibit GDH in MOGtreated intact MCF7 cells. We found a time-dependent increase in the absolute ( Supplementary Fig. 12c and Methods) [NOG] ic that, after 8 h, reached 29 mM, thereby exceeding the levels required to substantially inhibit GDH (Fig. 6c) .
Intriguingly, the K d NOG of GDH was tenfold higher than that reported for IDH 36 , thus suggesting that, at a given MOG concentration, glutamine metabolism would be more susceptible to inhibition in the reductive than in the oxidative direction. In agreement with this possibility, 125 µ M MOG caused a significant decrease in the production of citrate m + 5 from [U-13 C]glutamine but did not significantly affect the citrate m + 4 species at concentrations below 0.5 mM (Fig. 6d) . These data suggested that the metabolic effects of MOG depend on the [NOG] ic in a manner that reflects the relative potency of NOG toward its intracellular targets.
Finally, the finding that GDH is a target of MOG raised the possibility that expression levels of low-affinity targets might determine sensitivity to MOG. However, neither GDH nor IDH transcript abundance correlated with IC 50 DMOG in our initial analysis ( Supplementary Dataset 1) . Given that MCT2 is required for NOG to reach sufficiently high concentrations to inhibit low-affinity targets, we asked whether the expression of genes involved in glutamine metabolism might correlate with IC 50 DMOG in a subset of cell lines that expressed high levels of MCT2 mRNA (Supplementary Dataset 2). Within this subset, expression of several transcripts associated with glutamine metabolism exhibited increased correlation with IC 50 DMOG compared with the corresponding correlation values derived from the entire cell-line panel (Fig. 6e,f) . However, none of these targets alone were able to predict sensitivity, in agreement with the idea that interference with multiple proteins by NOG contributes to toxicity. Notably, GDH mRNA expression showed the highest correlation with IC 50 DMOG among all genes involved in glutamine metabolism (Fig. 6e,f) .
Together, these data show that NOG directly binds and inhibits GDH with a high K d . Although other low-affinity targets will probably be inhibited at this [NOG] ic , this finding provides a rationale for the selective cytotoxicity observed only in cells that accumulate high [NOG] ic .
Discussion
In this study, we found that the methyl oxoacetate ester of DMOG is rapidly hydrolyzed in cell culture medium, thus producing MOG. MCT2 facilitates the transport of MOG into cells and thereby determines [NOG] ic . At high concentrations, NOG inhibits glutamine metabolism and consequently leads to ATP depletion and cytotoxicity. These new insights into the mode of action of DMOG provide important considerations for its use in mechanistic studies of α KG-dependent metabolism and signaling.
Despite the notion that relative lipophilicity determines drug entry into cells, increasing evidence suggests that most drugs enter cells via transporters 37 . Accordingly, transporter expression or polymorphisms can influence drug pharmacokinetics and pharmacodynamics, for example, as demonstrated for metformin and the transporter OCT1 (encoded by SLC22A1) 38 . In addition to MCT2 expression, which is increased in some human cancers 30, 39, 40 , additional factors, including the relative expression of other MCTs, may influence MOG uptake, also in normal tissues. MCT1 expression Articles NATure CHeMiCAl BiOlOGy in INS-1 cells also led to increased MOG entry, albeit to a lower level than MCT2, thus indicating that unless it is expressed at high levels, MCT1 is unlikely to significantly contribute to MOG uptake. Moreover, because MCT function requires cotransport of protons, MOG pharmacodynamics may be influenced by an acidic tumor microenvironment 29 . The availability of endogenous MCT2 substrates may also be dictated by the tissue microenvironment 41 , and we showed that pyruvate can outcompete MOG for cell entry.
The observation that high [NOG] ic persists in cells suggests minimal turnover, thus making MOG a suitable candidate to image 42 MCT2-positive tissues. Beyond its potential applications in cancer, the identification of MOG as an MCT2 substrate should provide mechanistic insights into the in vivo function of MCT2, a poorly understood transporter, as well as MOG pharmacodynamics.
Furthermore, our results indicate that high [NOG] ic is cytotoxic, owing to simultaneous targeting of multiple enzymes in glutamine metabolism. DMOG has been reported to decrease mitochondrial respiration and ATP levels in HCT116 cells 35 and to cause various metabolic effects, including depletion of TCA-cycle intermediates, in primary peripheral mononuclear cells 43 . However, the metabolic targets of NOG were previously unknown. Notably, we showed that HCT116 cells express sufficient MCT2 to confer sensitivity to MOG, and peripheral mononuclear cells 43 have also been reported to express MCT2 (ref. 44 ).
We found that depletion of TCA-cycle intermediates after MOG treatment was attributable to attenuated glutamine carbon entry into the TCA cycle, which can be mediated by two major pathways involving TAs or GDH. The pan-transaminase inhibitor AOA 
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NATure CHeMiCAl BiOlOGy did not recapitulate the effects of MOG on TCA labeling from glutamine, thus implicating GDH as the relevant NOG target. MOG also led to an increase in amino acid levels, which occurred after TCA-cycle inhibition and reflected a decreased α KG/Glu ratio, thereby indicating attenuated amino acid degradation through TAs. Finally, we also observed inhibition of RC, probably through IDH, which has been shown to be inhibited by NOG in vitro 36 . DM-α KG, which provides the product of GDH, restored 
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TCA intermediates and respiration in MOG-treated cells. This observation was associated with a partial rescue of MOG-induced cytotoxicity, thus further supporting the involvement of GDHmediated metabolic effects in cytotoxicity. We therefore used GDH to understand why toxicity occurs only in cells with high [NOG] ic . Comparison of the absolute [NOG] ic to the in vitro K d NOG of GDH supports a model in which GDH inhibition occurs only when [NOG] ic exceeds its K d NOG , thereby explaining why expression of MCT2, which drives high [NOG] ic , correlates with toxicity.
Beyond GDH, our findings suggest that the ability of NOG to interfere with multiple α KG-mediated processes ('polypharmacology' 45 ) underlies its effectiveness in disrupting cellular metabolism, thereby causing toxicity. Polypharmacology is emerging as a desirable trait in new drug development 37, 46 , as best exemplified by kinase inhibitors 47 . Consequently, further systematic studies are warranted to define the spectrum of intracellular NOG targets.
Our findings may also be relevant for the targeting of dioxygenases, for which competitive inhibition of the α KG-binding pocket is a common pharmacological strategy 9, 17 . The known IC 50 values of NOG for dioxygenases are in the micromolar range 17 . We showed that even when MCT function is low, [NOG] ic can reach millimolar concentrations, thus suggesting that many dioxygenases are likely to be inhibited, as also corroborated by the indistinguishable kinetics of HIF1α stabilization between MOG-sensitive and MOG-resistant cells. However, as more dioxygenases become better characterized, comparing their relative sensitivity to NOG will be of interest. The availability of isoform-specific PHD inhibitors should help elucidate the extent to which metabolic effects contributed to the action of DMOG in previous studies that explored the therapeutic potential of PHD inhibition. Finally, PHDs modulate metabolism in both an HIF-dependent and HIF-independent 48 manner. In particular, HIF-dependent gene expression leads to suppression of mitochondrial respiration 14, [25] [26] [27] 35, 49 , similarly to the direct effects of MOG. Use of DMOG to probe metabolic functions of dioxygenases should therefore be evaluated in the light of its instability, MCT2 expression and the actual concentration that NOG reaches in cells.
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NATure CHeMiCAl BiOlOGy . Spearman's rank correlation coefficient (ρ) was calculated for DMOG sensitivity against all genes. Because the data were normally distributed, we assumed a false discovery rate of 5% and therefore used a cutoff of ± 2 s.d. from the mean to define transcripts that were positively or negatively associated with DMOG IC 50 (Supplementary Dataset 1) . For Fig. 6e ,f, to investigate how intracellular target-gene transcripts correlated with sensitivity to DMOG, Spearman's rank correlation analysis was performed with only the top quartile of MCT2-expressing cell lines. This approach was based on the assumption that all high-MCT2-expressing cell lines accumulate [NOG] ic at sufficiently high levels to engage low-affinity intracellular targets, thereby alleviating the bias imposed by the dependence of DMOG sensitivity on MCT2 expression status (Supplementary Dataset 2).
Data and statistical analyses. For metabolomics analyses, data exported from Mass Hunter Workstation ('Gas chromatography-mass spectrometry' section) were analyzed with an in-house-generated R script. To generate heat maps, we expressed data as a log 2 -fold change relative to the appropriate control condition, averaged across all replicates and subsequently used to generate heat maps with the 'pheatmap' package, version 1.0.8 (https://CRAN.R-project.org/package= pheatmap/). Metabolites were ordered from those with the largest positive fold change to those with the largest negative fold change, on the basis of one of the conditions in each experiment, as indicated in the figure legend for the respective heat maps. All metabolomics data were corrected for natural isotope abundance with a script provided by Sean O'Callaghan (Bio21 institute, University of Melbourne).
Statistical analyses throughout this work were performed with GraphPad Prism 7.0b. Comparisons were made with two-sided unpaired t tests, two-sided multiple t tests with the Holm-Sidak method for multiple-comparison testing, one-way ANOVA with Dunnett's correction for multiple comparisons or two-way ANOVA with Tukey's test for multiple comparisons, as indicated in the figure legends.
To determine IC 50 values, an 'inhibitor concentration versus normalized response-variable slope' curve was fitted. To determine degradation rates, we fitted curves with the one-phase-decay model. To determine K d values, we used a onesite-specific binding-curve model. All curve fitting was performed with GraphPad Prism 7.0b with standard parameters.
Chemicals. DMOG (Cayman Chemicals, 71210), MOG (synthesized as described in the Supplementary Note or generated from DMOG by incubation of DMOG at 20 mM in RPMI medium for 16 h) or NOG (Santa Cruz, sc202720A) was used at 1 mM unless otherwise stated. 13 C-labeled tracers were obtained from Cambridge Isotope Laboratories, except for DM-13 C-α KG, which was synthesized in house (Supplementary Note). All other chemicals were obtained from Sigma unless otherwise stated. Bovine GDH was obtained from Sigma (G2626).
Cell lines, cell culture and viral transduction. All cell lines were obtained from the American Type Culture Collection. Human breast cancer cell lines (Fig. 1b) were obtained as an NCI-ICBP45 kit. All cell lines were cultured in RPMI 1640 medium (Gibco, 31840) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine and 100 U/ml penicillin/streptomycin in a humidified incubator at 37 °C and 5% CO 2 . In the case of INS-1 cells, the medium was also supplemented with 10 mM HEPES and 0.05 mM β -mercaptoethanol. All cell lines tested mycoplasmafree, and cell identity was confirmed by short-tandem-repeat profiling by the Francis Crick Institute Cell Services Science Technology Platform. Hypoxia treatment was carried out with an InVivo 2 400 humidified workstation (Ruskinn), set to 1% O 2 , 5% CO 2 and 70% humidity.
Retroviruses were produced in 293 T cells by cotransfection of pBabePurobased vectors containing the cDNA of interest and a plasmid containing the amphotropic receptor gene. 48 h after transfection, viral supernatants were harvested and supplemented with 4 µ g/ml polybrene, before being added to target cells for 6-8 h. Cells were allowed to recover for 24 h before selection with 1 µ g/ml puromycin (in all cells except for INS1, for which 0.25 µ g/ml puromycin was used) for at least 3 d.
Lentiviral transduction was performed as with retroviruses, but cotransfection of the pLVX-TightPuro-based vectors into 293 T cells was done with pMD2.G (VSV-G), pMDLg/pRRE (GAG/POL) and pRSV-Rev.
Cloning of expression constructs. Plasmids containing cDNAs of human
MCTs were as follows: MCT2 was obtained from OriGene (clone ID SC108858, NM_004731) and cDNAs for MCT1 (Dharmacon MHS6278-202806621, BC026317.1) and MCT4 (MHS6278-211688899, BC112267.1). cDNAs were amplified with the primers below and then cloned into pBabePuro or pLVX-TightPuro to enable retrovirus production. When these constructs were used, the results were always compared to those for a control cell line transduced with virus encoding empty pBabePuro or pLVX-TightPuro vector. The primers used can be found in Supplementary Table 1 .
For knockdown of MCT2, pLKO-vector-based shRNAs were obtained from Dharmacon (TRCN0000038504, sequence: GCAGGTAAATTGGTGGATTTA).
Generation of HIF1α-knockout cell line by CRISPR. CRISPR constructs
were designed and cloned as previously described 50 with minor modifications detailed below. CRISPR guide sequences (sgRNAs) were designed with the MIT CRISPR Design Tool (http://crispr.mit.edu/) (forward oligonucleotide, caccgTTCTTTACTTCGCCGAGATC; reverse oligonucleotide, aaacGATCTCGGCGAAGTAAAGAAc). Guide oligonucleotides were phosphorylated with T4 polynucleotide kinase (New England BioLabs) and annealed in a thermocycler with the following parameters: 37 °C for 30 min, 95 °C for 5 min, temperature decrease to 25 °C at 0.1 °C/min. The empty Cas9 expression plasmid (pSpCas9(BB)-2A-Puro (PX459) V2.0) was linearized with BbsI, and annealed oligonucleotides were ligated in before transformation into DH5a Escherichia coli. Colonies were tested for successful insertion by colony PCR, with an expected band at 150 bp.
To generate knockout clones, we seeded MCF7 cells 24 h before transfection with the expression plasmid encoding Cas9 from Streptococcus pyogenes, the CRISPR target sequence and the puromycin-resistance marker. Transfection was performed at 70-90% confluency with FuGENE HD Transfection Reagent (Promega), according to the manufacturer's instructions. The day after transfection, puromycin (1 μ g/ml, P7255) was added to the medium for 72 h for selection. The following day, puromycin was removed, and cells were seeded at limiting dilutions to obtain monoclonal colonies (500-1,000 cells per 15-cm cell culture dish). Monoclonal populations were grown for 2 weeks, during which the medium was replaced every 2-3 d. Colonies (> 100 cells) were isolated and expanded until they could be tested for loss of the target protein by western blotting. Corresponding author(s): Dimitrios Anastasiou
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Experimental design 1. Sample size
Describe how sample size was determined. No sample size determination was performed. For metabolomics experiments, retrospective evaluation of data from pilot measurements indicated that 4 analytical replicates sufficed to yield statistical power that is acceptable for the value (<0.05) used in this manuscript to define experimental results as significant.
Data exclusions
Describe any data exclusions. In some metabolomics experiments, up to one replicate was allowed to be excluded when technical failure of the mass spectrometry measurement was evident based on poor ion peak quality. Small debris was excluded from flow cytometry analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings presented in this study were reproducible based on independent replicate measurements as described in detail in the corresponding figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For metabolomics analyses by GC-MS, samples were randomised using the relevant utility within the Agilent Chemstation software, and, for LC-MS analyses, randomisation was done using a random number generator in Microsoft Excel.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was used as the types of measurements conducted were not susceptible to subjective bias.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Graph plotting and statistical analysis: GraphPad Prism® 7.0b. In-house scripting: For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
DM-[13C5]-αKG and MOG were synthesised in-house and are available at limited quantities. All other materials are commercially available.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
